CEO Total Pay
$1.7M
FY2025 Summary Compensation, below median
The CEO earned $1.7M in FY2025 against median worker pay of $221,391 · Chemicals & Pharmaceuticals.
Data updated August 2026
Subscribe to Collegium Pharmaceutical, Inc CEO pay filing updates (RSS)
Answer first
According to the same FY2025 complete-filing cohort used on the rankings boards (CEO total, median worker, and ratio all present). Median worker pay is $221,391. Industry placement uses the FY2025 SIC-28 peer cohort (# 144 of 168, 15th percentile - among the lower quartile of industry peers by pay ratio). Figures come from Section 953(b) Dodd-Frank DEF 14A disclosures - not estimates. View all Chemicals & Pharmaceuticals companies.
Collegium Pharmaceutical, Inc CEO pay vs. every FY2025 complete filing
Total CEO compensation, the full national distribution, this company marked
$1,715,846 17th percentile higher than 17% of 1,423 companies
Each bar is a $2500K-wide band; taller bars hold more companies. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source SEC DEF 14A Section 953(b) disclosures, PlainCEOPay extract · FY2025
CEO total pay ($1.7M) against pay ratio (8:1) for Collegium Pharmaceutical, Inc (marked) and its 4 closest same-industry peers, against the Chemicals & Pharmaceuticals industry median on both axes.
Exclusive CEO-to-median-worker bands across 153 complete latest-FY filings in SIC 28. Segments sum to the peer set, not this company's compensation pillar.
A component-level pay breakdown is not reported in Collegium Pharmaceutical, Inc's structured SEC pay-ratio disclosure. See our methodology →
Complete DEF 14A pay-ratio filings for this CIK across FY2021–2025. Year-over-year deltas compare adjacent filing years only; incomplete dollar rows are omitted (same completeness gate as the hero figures).
| FY | CEO pay | Δ pay | Median worker | Pay ratio | Δ ratio |
|---|---|---|---|---|---|
| 2021 | $179K | - | $178,969 | 9:1 | - |
| 2022 | $162K | -9.3% | $162,407 | 43:1 | +34:1 |
| 2023 | $9.0M | +5472% | $215,476 | 42:1 | -1:1 |
| 2024 | $12.1M | +34% | $223,542 | 54:1 | +12:1 |
| 2025 | $1.7M | -86% | $221,391 | 8:1 | -46:1 |
Source: SEC EDGAR DEF 14A pay-ratio disclosures for CIK 1267565, FY2021–2025. Adjacent-year deltas only.
Collegium Pharmaceutical, Inc's FY2025 ratio 8:1 ranks #144 of 168 Chemicals & Pharmaceuticals filers (15th percentile). the CEO earned 8× the median employee ($221,391) in FY2025.
At $221,391 median worker pay, the FLOOR stamp is near pay-parity territory under LIGHT CEO total.
CEO Total Pay
$1.7M
FY2025 Summary Compensation, below median
Pay Ratio
8:1
Below typical
Collegium Pharmaceutical, Inc's FY2025 ratio 8:1 ranks #144 of 168 Chemicals & Pharmaceuticals filers (15th percentile). The structured pay-ratio disclosure reports the total without line-item components. Chemicals & Pharmaceuticals (SIC 28) median ratio is 42:1 across 168 FY2025 filers; Collegium Pharmaceutical, Inc's $1.7M CEO total is at or below the $7.9M industry median CEO pay.
Dollar rank #1177 and ratio rank #1296 split - treat 8:1 as a disclosure, not a fairness score. Open Chemicals & Pharmaceuticals peers.
Read our methodology - how this data is sourced, computed, and verified. Collegium Pharmaceutical, Inc's FY2025 ratio 8:1 ranks #144 of 168 Chemicals & Pharmaceuticals filers (15th percentile).
ABS(ceo_total_comp) peers first, then a SIC pole and a stamp-branched guide - not a fixed Related strip. This page stamps FLOOR · LIGHT · ELITE-MED.
ABS(ceo_total_comp) peer at $1.7M (Δ $274 heavier vs Collegium Pharmaceutical, Inc); MODEST · PAR-MED vs this page's FLOOR · LIGHT · ELITE-MED.
ABS(ceo_total_comp) peer at $1.7M (Δ $32K heavier vs Collegium Pharmaceutical, Inc); FLOOR · HIGH-MED vs this page's FLOOR · LIGHT · ELITE-MED.
ABS(ceo_total_comp) peer at $1.8M (Δ $36K heavier vs Collegium Pharmaceutical, Inc); STEEP · LOW-MED vs this page's FLOOR · LIGHT · ELITE-MED.
ABS(ceo_total_comp) peer at $1.7M (Δ $38K lighter vs Collegium Pharmaceutical, Inc); FLOOR · HIGH-MED vs this page's FLOOR · LIGHT · ELITE-MED.
Omeros Corp stamps FLOOR · LIGHT nearest in-SIC by ABS(pay_ratio) to Collegium Pharmaceutical, Inc's FLOOR filing.
Collegium Pharmaceutical, Inc's FY2025 package sits #1177 by CEO dollars and #1296 by ratio under LIGHT · FLOOR.
Collegium Pharmaceutical, Inc's FLOOR stamp sits in the lower Item 402(u) band - start with how the ratio is disclosed before comparing peers.
Data currency: Executive compensation from SEC EDGAR DEF 14A proxy statements through fiscal year 2025, compiled and last refreshed August 2026. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.